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Ovarian germ cell survival is dependent upon the formation of primordial follicles, which occurs during fetal life in the human. Activin
contributes to germ cell proliferation and survival at this time. SMADs2 and 3 are central elements in the activin signalling pathway and thus
indicate sites of activin action. We have investigated the expression and localisation of SMADs2 and 3 in the fetal ovary between 14 and 20 weeks
gestation, i.e. preceding and during primordial follicle formation. SMAD3 mRNA expression increased 1.9 fold (P=0.02). SMAD2 and 3 proteins
were localised by immunofluorescence to the nuclei of three distinct populations of somatic cells: (a) stromal cells between clusters of germ cells;
(b) some somatic cells intermingled with activin βA-expressing germ cells; (c) pre-granulosa cells surrounding primordial follicles. Germ cells did
not express SMAD2 or 3. Activin A increased and follistatin decreased phosphorylation of SMAD2/3 in vitro, and activin increased SMAD2 and
decreased KITLG mRNA expression. It therefore appears that somatic cells are the targets for activin signalling in the developing ovary. The
effects of activin on germ cells are indirect and include mediation by the kit ligand/c-Kit pathway, rather than being an autocrine germ cell effect.
© 2007 Elsevier Inc. All rights reserved.Keywords: Fetal ovary; Smad2/3; Activin; Kit ligand; c-Kit; Primordial follicleIntroduction
The key step in germ cell survival during ovarian develop-
ment is the formation of primordial follicles, these then
determining the reproductive lifespan of the ovary. In human,
they are formed during fetal life, from approximately 18 weeks
of gestation. Following migration of primordial germ cells
(PGCs) from the extraembryonic mesoderm of the yolk sac to
the genital ridge, sexual differentiation occurs at approximately
8 weeks gestation (i.e. 6 weeks post conception) in the human.
Initially the germ cells undergo mitotic proliferation, reaching
maximum numbers at around mid gestation (Baker, 1963).
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doi:10.1016/j.ydbio.2007.11.026intermingling somatic cells and are surrounded by a meshwork
of ovarian stroma (Pepling and Spradling, 2001; Sawyer et al.,
2002). Following entry into meiosis, germ cell loss through
apoptosis (De Pol et al., 1997; Vaskivuo et al., 2001) results in
less than 20% surviving to birth (Baker, 1963). Oocytes become
individually surrounded by somatic cells forming primordial
follicles (Hirshfield, 1991) which determines oocyte survival
and thus protects against apoptosis (Fulton et al., 2005). Both
cell types are believed to play an active role in the process of
follicle development, but the molecular mechanisms regulating
this interaction are still largely unknown. However, a number of
key genes have been identified as being required for the
formation of a normal complement of primordial follicles
(Matzuk, 2000; Amleh and Dean, 2002; Skinner, 2005). These
include growth factors and their receptors, e.g., kit ligand and its
receptor c-Kit (Manova et al., 1993; Richards, 2001; Robinson et
al., 2001; Klinger and De Felici, 2002), the neurotrophin
receptor TrkB (Dissen et al., 1995; Ojeda et al., 2000; Anderson
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factors (Dean, 2002; Bayne et al., 2004; Rajkovic et al., 2004).
Activin is one of several identified transforming growth
factor β (TGFβ) family members with major roles in
folliculogenesis (Findlay et al., 2002; Knight and Glister,
2003, 2006; Shimasaki et al., 2004). Members of this super-
family can influence several aspects of cell lineage and activity
including proliferation, differentiation, adhesion, motility and
apoptosis. Many are involved in embryonic development as
well as in adult tissue homeostasis (Mishina et al., 1999; Padgett
and Patterson, 2001). Activin subunits, but not the inhibin α
subunit, are present in the developing human fetal ovary, and
activin may contribute to the regulation of germ cell survival
and proliferation (Martins da Silva et al., 2004). The activin βA
subunit is expressed by clusters of germ cells immediately
preceding primordial follicle formation, but not by oocytes
within primordial follicles (Martins da Silva et al., 2004).
Activin βA expression therefore appears at a stage when
oocytes are not expressing c-Kit after entry into meiosis, but is
reduced when oocyte expression of c-Kit reappears at diplotene,
i.e., at follicle assembly (Driancourt et al., 2000; Hutt et al.,
2006). In the mouse, follicle assembly occurs in the neonatal
period: treatment with activin during this time increased the
number of primordial follicles that formed (Bristol-Gould et al.,
2006). Activin signals through membrane-bound serine–
threonine kinase receptors, which are also expressed in the
developing ovary. Activin binds to a type II receptor which
recruits and phosphorylates a type I receptor, ALK4, which in
turn phosphorylates Smad2 and Smad3 proteins (Massague,
1998). Smad proteins are central elements in the activin receptor
signalling pathway: following activation by phosphorylation
they dimerise with Smad4 and translocate to the nucleus to
modulate target gene expression. Smads2 and 3 can also
mediate signalling by other TGFβ family members and thus are
not exclusive to activin (Massague, 1998). Smad2 and Smad3
have both been implicated as important factors in ovarian
development and function (Chang et al., 2002; Drummond et
al., 2003). It has also been demonstrated that Smad3 deficient
(Smad3−/−) mice have reduced fertility (Tomic et al., 2002,
2004) and show deficient granulosa cell proliferation. Identi-
fication of cell types expressing SMADs2 and 3 in the nucleus
therefore provides information as to the targets of activin or
other TGFβ factor signalling. We have made use of this in the
present study to identify the cells in the developing human
ovary which respond to and mediate the effects of activin on
germ cell survival. Furthermore we identify kit ligand (KITLG),
a key regulator of mammalian ovarian development (Driancourt
et al., 2000; Hutt et al., 2006), as a target of activin-regulated
transcriptional repression in the human fetal ovary.
Materials and methods
Tissue
Human fetal ovaries were obtained following medical termination of
pregnancy. Consent was obtained in accordance with national guidelines
(Polkinghorne, 1989) and the study was approved by the Lothian Research
Ethics Committee. Pregnancies were terminated by treatment with mifepristone(200 mg orally) followed 48 h later by misoprostal (800 mcg) three hourly per
vaginum. Ultrasound examination was used to determine gestation prior to
termination and this was subsequently confirmed by direct measurement of foot
length. Pregnancies were all terminated for social reasons and all fetuses
appeared morphologically normal.
Ovaries were removed from the fetus and processed in 3 ways. Ovaries were
either snap frozen and stored at −70 °C, fixed in Bouins solution for 2 h
followed by transferring to 70% ethanol before processing into paraffin using
standard methods, or prepared for tissue culture as described below.
Isolation of RNA and synthesis and amplification of cDNA
Total RNAwas extracted from snap frozen samples of fetal ovary (14–20 weeks)
or cell culture pellets/lysates (see below). This was performed using the RNeasyMini
Kit (Qiagen, Crawley, UK) with on-column DNase digestion according to the
manufacturer's instructions. Reverse transcription was performed using Expand
Reverse Transcriptase (Roche Diagnostics, Lewes, UK). Briefly, 1μg total RNAwas
incubated with 50 pmol oligo (dT)16 primer for 10 min at 65 °C and then placed on
ice. A reaction mix comprising buffer, 10 mmol/l Dithiothreitol, 1 mmol/l of each of
deoxynucleotide triphosphate (dNTP), RNasin ribonuclease inhibitor (Promega,
Southampton, UK) and 50 IU reverse transcriptase (RT+), was added to each tube in
a total volume of 20 μl. Equivalent reactions without reverse transcriptase provided
RT-controls. All tubes were then incubated at 42 °C for 1 h.
Amplification of SMAD2 and 3 cDNA by PCR
Target-specific PCR was performed using 1 μl of the RT+ or RT− cDNA
synthesis reactions or water as template in a reaction volume of 25 μl containing
2.5 IU of HotStar Taq DNA polymerase (Qiagen, Crawley, UK), 2.5 μl 10×##
reaction buffer giving a final concentration of MgCl2 of 1.5 mmol/l, 200 μmol/l
dNTP, and 500 nmol/l of appropriate forward and reverse primers. PCR
amplification conditions consisted of an hot start step at 95 °C for 15 min to
activate the enzyme, followed by 35 cycles of denaturation at 94 °C for 30 s,
annealing at 53 °C for 30 s and extension at 72 °C for 30s; a final extension
period at 72 °C for 10 min completed the amplification. SMAD2 and 3 primers
were designed to span an intron to ensure that genomic DNAwas not amplified.
Primers for the constitutively expressed gene GAPD were used to confirm the
integrity of the RNA and efficacy of the PCR reaction. Primers (MWG,
Ebersberg, Germany) were: GAPD: forward GACATCAAGAAGGTGGT-
GAAGC, reverse GTCCACACCCTGTTGCTGTAG, SMAD2: forward
AACAGGACGATTAGATGAGC, reverse GACCTGGTTTGTTCAGA-
GAAGC SMAD3: forward TGAGGCTGTCTACCAGTTGACC, reverse
CTAAGACACACTGGAACAGCGG. PCR products were separated on 2.5%
agarose gels stained with GelRed (Cambridge Bioscience, Cambridge, UK) and
visualised and photographed under UV transillumination.
Real-time quantitative PCR and densitometric analysis
Quantitative real-time RT-PCR was performed using the Lightcycler (Roche
Diagnostics Ltd, Welwyn Garden City, UK) as described previously (Hartley et
al., 2002). Reverse-transcribed RNA samples were diluted in water, and 1 μl of
diluted first-strand cDNA was added to a final volume of 10 μl containing
0.5 μmol/l each of forward and reverse primer in 1× Quantitect SYBR Green
PCR Master Mix (Qiagen, Crawley, UK). Signal acquisition was performed for
each of 45 amplification cycles followed by continuous melt curve analysis to
ensure product accuracy. GAPD, SMAD2 and SMAD3 primers are described
above. FGF2 primers have been described previously (Battersby et al., 2007).
Standard curves for GAPD, SMAD2, SMAD3 and FGF2 were derived using
a series of dilutions (1/10 to 1/10,000) of first-strand cDNA from an 18 week
ovary. The number of cycles needed to yield a fluorescent signal above
background (the cross-over point, Cp) at each dilution was plotted against the
log of relative concentration using LightCycler Software (Molecular Dynamics
Ltd, Chesham, UK). The dilutions yielded a straight line for each product,
confirming that Cp is a good indicator of target concentration across at least 3
orders of magnitude. For quantification, cDNAs were used at 1/10 dilutions with
all amplification reactions performed in duplicate. Relative concentrations were
calculated from Cp values using the slope of the appropriate standard curve
Fig. 1. (A) Expression of mRNA for SMAD2 and 3 in human fetal ovary. RT-
PCR analysis of samples extracted from human fetal ovaries at 14 and 19 weeks
gestation. Lanes marked 14- and 19-contained samples in which reverse
transcriptase was omitted. W refers to water instead of cDNA in the PCR
reaction. (B) Real-time PCR quantification of SMAD2 and 3 expression in the
fetal ovary. Expression of SMAD2 and 3 mRNAwas quantified in human fetal
ovary specimens over the gestational range of 14–20 weeks. Data calculated as
mRNA expression relative to GAPD and expressed as fold increase over
expression at 14 weeks. n=4–7 per group, mean±SEM.). There was a
significant increase in SMAD3 but not SMAD2 mRNA expression over this
gestational range (P=0.02). (C) Immunoblot for SMAD 2/3 and phosphorylated
SMAD2/3 proteins in human fetal ovary at 14 and 18 weeks gestation, and
negative control (18 weeks). Molecular weight markers as indicated.
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for FGF2. Calculation of SMAD2, SMAD3 and FGF2 mRNA concentrations
were made relative to GAPD from the same sample to allow comparisons
between cDNAs.
Expression of KITLG mRNA were below quantifiable levels using the
quantitative PCR method above. For KITLG detection conventional 20 μl PCR
reactions containing 1 μl of cDNA for either KITLG or the constitutively expressed
control geneRPL32were performed and products separated on agarose gels using the
concentrations and methods detailed above. Primers used were hRPL32-F 5′-
CATCTCCTTCTCGGCATCA-3′ and hRPL32-R 5′-AACCCTGTTGT-
CAATGCCTC-3′, primers to KITLG have been described previously (Reber et al.,
2006). 35 and 30 cycles of PCRwere used to amplifyKITLG andRPL32 respectively
to avoid saturation.Gelswere photographed underUV transillumination and captured
gel images imported into ImageJ (NIH, Bethesda) for densitometric analysis.KITLG
mRNA levels were calculated relative toRPL32. Data presented for the expression of
SMAD2, SMAD3, FGF2 and KITLG are mean±sem of four independent culture
experiments. Significance was determined by t-test.
Immunofluorescence of SMADs2 and 3, c-Kit, and activin βA
Paraffin-embedded ovaries were cut into 5μm sections and mounted onto
electrostatically charged microscope slides (VWR, Poole, UK), dried overnight,
and then dewaxed and rehydrated using conventional methods. Antigen retrieval
was performed by boiling the slides in citrate (0·01 M) for 2 min followed by
immediate cooling in cold water. Endogenous peroxidases were quenched in 3%
hydrogen peroxide in methanol for 30 min at room temperature. After a wash in
water, slides were transferred into phosphate-buffered saline (PBS) (Gibco) for
5 min and blocked for 30 min in normal goat serum (Diagnostics Scotland,
Carluke, UK) diluted 1:4 in PBS containing 5% BSA. SMAD2 and SMAD3
antibodies (both Zymed, Paisley, UK) diluted 1:60 and 1:100 respectively and c-
Kit antibody (without antigen retrieval; Dako Cytomation, Ely, UK) diluted 1:30
were applied to sections at 4 °C overnight in a humidified chamber. SMAD2 and
3 and c-Kit were visualised by tyramide-enhanced fluorescein (Perkin Elmer
Life Science, Massachusetts, USA) via a peroxidase conjugated goat anti-rabbit
secondary antibody (Dako, Glostrup, Denmark) diluted 1:200. Sections were
counterstained with propidium iodide (Sigma) diluted 1:1000. Slides were then
washed in PBS and mounted in aqueous mounting medium (Permafluor; High
Wycombe, UK). Fluorescent images were captured using a LSM510 confocal
microscope (Zeiss). Negative controls were incubated with non-immune rabbit
IgG, omitting primary antisera.
To assess the relative nuclear localisation of SMADs 2 and 3 across
increasing gestational age, pixel counts were made of unselected images of
sections of fetal ovary at 14–16 and 18–19 weeks gestation. To ensure
comparability, all sections were immunostained at the same time for each
protein, and images were captured using the same laser settings on the confocal
microscope. Data were calculated as the number of pixels of nuclear SMAD
(i.e., yellow) as a percentage of total SMAD (i.e., green). Correction for the
amount of nuclear counterstain (i.e., red, propidium iodide) was also
investigated, but this did not alter the findings.
For dual staining of SMAD3 or c-Kit with activin βA, sections were treated as
above to the serum blocking stage then blocked with avidin (0.01M; 15 min) and
then biotin (0.001M; 15 min; both from Vector Laboratories, Peterborough, UK)
with washes in PBS in between. Activin βA antibody (gift from NP Groome) was
diluted 1:200 and applied to sections at 4 °C overnight in a humidified chamber.
Activin βA was visualised by incubating with the secondary antibody goat anti-
mouse Alexa 546 (Molecular Probes, Leiden, The Netherlands), diluted 1:200 in
PBS. Slides were blocked for a further 30 min in normal serum and then Smad3
antibody diluted 1:100 or c-Kit antibody diluted 1:30 were applied to sections at
4 °C overnight in a humidified chamber. SMAD3 and c-Kit were visualised as
above by tyramide-enhanced fluorescein (Perkin Elmer Life Science). Sections
were counterstained with To-Pro (Molecular Probes) diluted 1:1000. Slides were
then washed in PBS and mounted before image capture as indicated above.
Immunoblotting
Fetal ovaries or cell pellets (see below) were homogenized in lysis buffer
containing 80 mM Tris–HCl (pH 6.8), 1% (vol/vol) glycerol, 1% (wt/vol)sodium dodecyl sulfate and a Complete Mini protease inhibitor cocktail tablet
(Roche Diagnostics, Mannheim, Germany). Total protein quantification was
performed using the BioRad protein assay kit.
Proteins were boiled in a 1:3 volume of 4× reduced sample buffer [20%
250 mM Tris–HCl (pH 6.8), 4% sodium dodecyl sulfate, 10% β-mercaptoetha-
nol and 0.1% bromophenol blue]. Ten micrograms of total protein were loaded
onto 15% SDS-PAGE gels with high-molecular weight Rainbow protein
markers (Amersham Biosciences, Buckinghamshire, UK) run in parallel. Gels
were blotted onto polyvinyl difluoride membrane (Hybond P, Amersham
Biosciences) and then blocked in TBS and Tween [10 mM Tris–HCl (pH 7.5),
150 mM NaCl, 0.1% Tween 20] containing 5% powdered milk before overnight
incubation at 4 °C with primary antibody which was omitted in negative
controls. Goat polyclonal antibodies to Smad2/3 and phosphorylated Smad2/3
(Santa Cruz, CA, USA) and β-actin (Santa Cruz) were diluted 1:500, 1:500 and
1:1000 respectively in TBS and Tween 20 containing 5% powdered milk. Bound
antibody was detected using horseradish peroxidase-linked secondary anti-
bodies diluted 1:10000 (Santa Cruz). Proteins were revealed and visualized
using the enhanced chemifluorescent system (Amersham Biosciences) and
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(Amersham Biosciences) with normalisation for protein loading using β-actin.
Culture of disaggregated human fetal ovary
Fetal ovaries were collected as described above. Both ovaries from a single
fetus were placed in Hanks' balanced salt solution (HBSS) (Gibco) and pulledFig. 2. Immunofluorescent localisation of SMAD2 and 3 and activin βA in the hu
negative control for both SMAD2 and 3; (B and C) 19 weeks gestation. SMAD3: (D)
E show increased stromal cell expression of both SMAD2 and 3 respectively at 18–19
granulosa cells of primordial follicles. Positive staining for SMAD2 and 3 is green and
and 3 are yellow. (G and H) Dual staining for SMAD3 and activin βA. (G), 18 week
pre-granulosa cells surrounding activin βA-expressing germ cells as well as in soma
oocytes within primordial follicles do not express activin βA but SMAD3 express
primordial follicles. Positive staining for activin βA is red, SMAD3 green and sectio
stroma; g, pre-granulosa cells; o, oocyte; pf, primordial follicle. Scale bars: all 20 μapart under the dissection microscope using 18 gauge needles. 500 μl
Collagenase Type IV (0.01 g in 1 ml HBSS) (Sigma, Dorset, UK) was added
and incubated for 10 min at 37 °C on a roller. Cells were shaken and incubated
again for a further 5 min. Fifty μl DNase 1 (0.007 g in 1 ml HBSS) (Sigma) was
added to the suspension and incubated for a further 5 min. The resulting single
cell suspension was centrifuged for 5 min at 500 g, the supernatant removed and
the cell pellet resuspended in HBSS (Gibco). This wash was repeated twice. Theman fetal ovary. SMAD2: (A) 14 weeks gestation, insert shows representative
14 weeks gestation; (E) 18 weeks gestation (F) 19 weeks gestation. Panels B and
weeks compared to 14 weeks. Panels C and F show SMAD2 and 3 expression in
sections were counterstained with propidium iodide (red), thus nuclear SMAD2
s gestation ovary (insert shows negative control) showing SMAD3 expression in
tic cells out-with germ cell clusters. (H) 19 weeks gestation ovary showing that
ion persists from somatic cells within germ cell clusters to granulosa cells of
ns were counterstained with To Pro (blue), thus nuclear SMAD3 is turquoise. s,
m.
Fig. 3. Immunoblot analysis of the effect of activin βA and follistatin on the
expression of phosphorylated SMAD2/3 protein, relative to β-actin. Addition of
100 ng/ml activin increased phosphorylated SMAD2/3 expression to 3.7±1.3
fold greater than control, mean±SEM, (*P=0.02, n=5, Student's t test)
whereas addition of 0.4 mg/ml follistatin resulted in a reduction of
phosphorylated SMAD2/3 expression to 19%±6.5% of control, mean±SEM.
(**P=0.01, n=4, Student's t test). Panel A shows results of quantification,
panels B shows representative immunoblots showing the effect of activin and
follistatin respectively.
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phenol red (Gibco) supplemented with 2 mM sodium pyruvate, 2 mM L-
glutamine, 1× ITS supplement (Sigma) and 3 mg/ml BSA, and with penicillin,
streptomycin and amphotericin. Treatments consisted of either 0.4 mg/ml
follistatin (Sigma) or 100 ng/ml recombinant human activin A (R&D systems,
Abingdon, UK). Cells were cultured for 36 h (for protein extraction) or 24 h (for
RNA extraction) in a humidified incubator (37 °C, 5% (v/v) CO2). At the end of
culture, cells were collected, washed in PBS (Gibco) and the pellets snap frozen
for protein extraction. For RNA extraction, floating non-adherent cells were
collected by centrifugation and resuspended in lysis buffer (RNeasy Kit,
Qiagen). The remaining adherent cells were lysed directly in the dish as
recommended by the manufacturer and the lysates pooled before RNA
extraction as detailed above. Protein analysis by immunoblotting was performed
as described above.
Results
SMAD2 and 3 mRNA expression
SMAD2 and 3 expression in the human fetal ovary was
demonstrated by RT-PCR across the mid-trimester (Fig. 1A).
SMAD2 and 3 mRNA expression was quantified across the
gestational range 14–20 weeks by real-time quantitative RT-
PCR (Fig. 1B, n=20 specimens). This demonstrated a small
increase in SMAD2 expression, up to 1.7±0.2 fold at 19–
20 weeks compared to 14 weeks, which did not reach statistical
significance. SMAD3 mRNA expression also showed an
increase which did reach statistical significance (P=0.02,
Kruskal–Wallis test) with highest expression at 17–18 weeks
gestation (1.9±0.3 fold increase vs. 14 weeks). This gestation
coincides with the stage at which primordial follicles are first
seen.
SMAD2 and 3 proteins in human fetal ovary
Immunoblotting demonstrated the expression of SMAD2/3
and phosphorylated SMAD2/3 proteins in the mid-trimester
human fetal ovary (Fig. 1C). Expression of SMADs2 and 3
were localised by confocal immunofluorescence microscopy in
all specimens of human fetal ovary examined between 14 and
20 weeks gestation (Fig. 2). Essentially similar results were
obtained for both SMAD2 and SMAD3. Three cell types
expressing SMADs2 and 3 were identified. Firstly, SMADs2
and 3 was localised to the nuclei of somatic cells in the ovarian
stroma between the clusters of germ cells (sex cords). Fewer
cells showing nuclear SMADs2 and 3 were identified at
14 weeks gestation compared to later gestation when the great
majority of such cells showed nuclear expression of SMADs2
and 3 (Fig. 2, A vs. B and D vs. E for SMAD2 and SMAD3
respectively). Confirming this visual impression, quantification
indicated that there was an increasing nuclear localisation of
both SMAD2 and SMAD3 with increasing gestation. The
proportion of SMAD2 that was nuclear rose from 3.6±0.8% at
14–16 weeks to 33.7±12.0% at 18–19 weeks, and that of
SMAD3 rose from 14.0±2.3% to 33.3±3.2% (both pb0.001,
n=16–18 in each case).
Secondly, SMADs2 and 3 were expressed by some somatic
cells intermingled with germ cells (Figs. 2B and E). A minority
of these cells expressed SMADs2 or 3. Thirdly, SMADs2 and 3were also localised to the nuclei of pre-granulosa cells
surrounding oocytes that had formed (or were in the process
of forming) primordial follicles (Figs. 2C and F). No expression
was seen in oocytes at any developmental stage.
This pattern of expression was strikingly different to the
pattern of expression of activin βAwe have previously reported
(Martins da Silva et al., 2004). Dual staining for SMAD3 and
activin βA was therefore performed. These experiments
confirmed previous findings (Martins da Silva et al., 2004),
that activin is expressed by the larger germ cells, generally
arranged in clusters and located towards the centre of the ovary,
but with no expression in oocytes within primordial follicles.
This technique allowed the demonstration that the activin-
expressing oocytes within the germ cell nests were adjacent to
somatic cells expressing SMAD3 (Figs. 2G and H). However
the pre-granulosa cells surrounding primordial follicles
expressed SMAD3 without expression of activin by the oocyte.
The prominent expression of SMAD3 in the somatic cells in the
cell streams also appeared not to be adjacent to activin-
expressing germ cells.
Fig. 4. Repression of KITLG expression by activin A signalling and c-Kit/activin βA immunolocalisation. (A) Semi-quantitative PCR analysis showing repression of
KITLG expression in disaggregated fetal ovary cultures treated with activin A. RPL32 levels remain constant showing equal amounts of RNAwere used in each cDNA
synthesis. Two representative experiments are shown, using ovarian tissue of 14 and 17 weeks gestation as indicated. W: water instead of cDNA in the PCR reaction.
(B) Densitometric quantification (n=4) shows significant decrease in KITLG expression in activin A treated ovarian cell cultures compared to control. FGF2
expression in the same experiments remains unchanged indicating specificity of the effect on KITLG. (C–E) Immmunofluorescent photomicrographs of human fetal
ovaries at 14 and 20 weeks gestation stained for c-Kit (green). Germ cells appear homogenously immunopositive for c-Kit expression at 14 weeks. At 20 weeks
gestation, c-Kit immunopositive germ cells are present near the periphery of the ovary (D, arrowheads) with immunonegative germ cells away from the subepithial
zone (arrows). More centrally at 20 weeks (E) germ cells in clusters do not express c-Kit (arrows), however expression resumes after primordial follicle formation (pf:
primordial follicle). (F, G, H) Dual immunofluorescence staining of c-Kit (green) and activin βA (red) in fetal ovary at 19 weeks gestation illustrating that c-Kit is not
expressed in the germ cells that show most pronounced activin expression. (F) Separated image of c-Kit expression, (G, H) combined c-Kit and activin βA expression.
Arrows, germ cells expressing activin βA but not c-Kit. Sections were counterstained with To Pro (blue). Scale bars: all 50 μm.
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SMAD2/3
The effects of activin and follistatin on phosphorylation of
SMAD2/3 protein were investigated using an in vitro culturesystem. Ovaries were disaggregated and a single cell suspen-
sion, containing both germ cells and somatic cells, was treated
with activin or follistatin for 36 h. Addition of 100 ng/ml activin
increased phosphorylated SMAD2/3 expression to 3.7±1.3 fold
greater than control (P=0.02, n=5) whereas addition of 0.4 mg/
195S.M. Coutts et al. / Developmental Biology 314 (2008) 189–199ml follistatin resulted in a reduction of phosphorylated SMAD2/
3 expression to 19±6.5% of control (P=0.01, n=5, Fig. 3).
Activin represses expression of kit ligand whilst stimulating
expression of SMADs2 and 3
Regulation of possible downstream transcriptional targets of
activin signalling was also investigated using the in vitro culture
system with expression of candidate genes determined by
quantitative and semi-quantitative RT-PCR.
Treatment with 100 ng/ml activin A for 24 h resulted in a
marked upregulation of SMAD2 mRNA levels to 6.9±2.7 fold
greater than control, (P=0.05, n=4). A smaller increase in
SMAD3 expression (4.0±1.3 fold greater than control, n=4)
was also detected, however it did not reach statistical
significance.
To determine whether germ cell-derived activin A regulated
the transcription of somatic cell produced factors that might in
turn influence germ cell growth and/or development we
examined the expression of two such known regulators, kit
ligand (KITLG) and basic Fibroblast Growth Factor (FGF2).
Expression of KITLG mRNA was readily detectable in both
fresh and disaggregated ovary but too low to be reliably
analysed using the quantitative RT-PCR method used. A semi-
quantitative RT-PCR with densitometric analysis was therefore
performed. Treatment with activin A reduced KITLG transcrip-
tion to less than two-thirds of that in control ovarian cells (61±
5% of control, P=0.04, n=4, Figs. 4A and B). Expression of
FGF2 remained unchanged by activin (101±5% of control,
n=4, Fig. 4B), indicating the specificity of the effect of activin
on KITLG expression.
Germ cells expressing activin βA do not express c-Kit
As KITLG encodes the ligand for the tyrosine kinase
receptor c-Kit, we re-analysed the expression of this receptor
(Robinson et al., 2001) in the second trimester fetal ovary. At
14 weeks gestation immunofluorescent confocal microscopy
demonstrated that all germ cells expressed membrane-bound c-
Kit protein (Fig. 4C). At later gestations however, separate
populations could be identified based on germ cell size, location
and c-Kit expression. Germ cells near the periphery of the ovary
continued to express c-Kit as at 14 weeks (Fig. 4D, arrow-
heads). However expression was more variable away from the
subepithelial zone (Fig. 4D) with those germ cells in clusters
mostly not expressing c-Kit (Figs. 4D and E). Oocytes that had
formed or were in the process of forming primordial follicles re-
expressed c-Kit protein at the membrane (Fig. 4E). This pattern
of expression, as previously reported (Hoyer et al., 2005), is
consistent with downregulation of the c-Kit receptor as germ
cells enter meiosis and subsequent upregulation as germ cells
form primordial follicles.
As c-kit expression is dependent on kit ligand and activin
represses kit ligand expression, we hypothesised that germ cells
that express activin would show reduced expression of c-Kit.
Germ cells that express c-Kit but not activin include peripheral
germ cells at earlier gestations and oocytes in primordialfollicles (Figs. 4C–E) (Martins da Silva et al., 2004) but the
situation in germ cells intermediate to these developmental
stages is unclear. Dual immunofluorescent staining for activin
βA and c-Kit was used to investigate this, and clearly showed
that activin βA-expressing germ cells in the germ cell clusters
did not express c-Kit, whereas nearby germ cells did.
Discussion
Activin has previously been shown to play a role in the
regulation of germ cell proliferation/survival during the
developmental period leading up to primordial follicle forma-
tion in the human (Martins da Silva et al., 2004) and to promote
postnatal primordial follicle assembly in the mouse (Bristol-
Gould et al., 2006). The present data indicate this effect is
mediated indirectly via somatic cells rather than directly on
activin-expressing germ cells, demonstrate that activin signal-
ling is via SMAD2/3 phosphorylation, and indicate that activin
downregulates KITLG expression, which may constitute the
reciprocal somatic to germ cell signal.
Activin binds to ActRIIA and ActRIIB serine–threonine
kinase receptors which then recruit a type 1 receptor (ALK4,
also known as ActR1A) with subsequent activation of the Smad
signalling pathway. The distribution of these receptor subtypes
in the human fetal ovary is widespread, with the type II
receptors expressed by both germ and somatic cells, although
ALK4 was predominantly expressed by the meshwork of
ovarian somatic cells surrounding the germ cell nests and by
some pre-granulosa cells intermingled with the germ cells
(Martins da Silva et al., 2004). Thus, the target cells for activin
signalling have, until now, been unclear. Nuclear expression of
the ‘receptor Smads’, Smad2 and Smad3, is evidence of active
activin or other TGFβ factor signalling in that cell. Smad2 and
Smad3 have been demonstrated in the postnatal ovaries of
mammals (Xu et al., 2002; Drummond et al., 2003; Billiar et al.,
2004) and have been demonstrated to play a role in
folliculogenesis (Xu et al., 2002). They have both been
implicated as important factors in ovarian development and
function (Chang et al., 2002; Drummond et al., 2003). However,
SMAD2 and SMAD3 have not previously been demonstrated in
the human fetal ovary.
In addition to activin, TGFβ, GDF9 and Nodal also signal
through Smad2 and Smad3 (Shimasaki et al., 2004). One
previous study has investigated expression of TGFβ1, TGFβ2
and TGFβ3 and of type I and II TGFβ receptors during the
development of the human fetal ovary (Schilling and Yeh,
1999). Both ligands and receptors were expressed predomi-
nantly by oocytes, i.e. distinctly different from the present data
localising SMADs 2 and 3 to somatic cell nuclei, thus it is
difficult to reconcile those data on expression of TGFβ and its
receptors with the present data. Gdf9 is expressed by oocytes in
primary follicles in rodents and in primordial follicles in cows
and sheep, but is not expressed prior to primordial follicle
formation (McGrath et al., 1995; Bodensteiner et al., 1999;
Jaatinen et al., 1999; Elvin et al., 2000; McNatty et al., 2001).
There is no evidence for the presence of GDF9 in the
developing human fetal ovary. Thus GDF9 is also unlikely to
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stages of development in the present study. There are no data
regarding the presence of NODAL in the human ovary.
Mouse models have been generated that are deficient in
Smad3 and activin proteins. Two different mouse models with a
homozygous deletion in Smad3 have been developed, with
differing effects on fertility. Those with a deletion in Smad3
exon 8 have reduced fertility compared with the wild-type, with
this being due to impaired follicular development (Tomic et al.,
2002). Deletion of Smad3 did not appear to affect the size of the
primordial follicle pool in the neonatal period, but altered
growth of follicles to antral stages in postnatal life (Tomic et al.,
2002). In contrast, mice with a deletion of Smad3 in exon 2
were fertile (Zhu et al., 1998). It has been proposed that deletion
in exon 8 disrupts a region that interacts with the receptors,
whereas deletion in exon 2 prevents the production of the active
domain of Smad3 (Tomic et al., 2004). Mouse models with
mutations in the gene encoding the activin βA subunit are
lethal. These mice develop to term but have secondary palate
defects and lack whiskers and lower incisors, dying within 24 h
of birth due to feeding difficulties (Matzuk et al., 1995).
Unfortunately, no conclusions are reached regarding ovarian
follicular development. Mouse models lacking the activin βB
subunit suffer eye lesions as a result of failed eyelid fusion.
These females do not show a disruption in follicular develop-
ment (Vassalli et al., 1994). Highly increased βA expression
was noted in the ovaries of these βB-deficient female mice,
suggesting the possibility of functional compensation within the
TGFβ superfamily. Using a gene knock-in approach, it has been
found that activin βB can rescue the craniofacial defects and
neonatal lethal phenotype of βA-deficient mice. However,
activin βB was unable to substitute for all the functions of βA.
The βB knock-in mouse is subfertile and has smaller ovaries
than those of controls (Brown et al., 2000). This suggests that
activin βA expression is necessary for development of the
correct complement of germ cells in the mouse ovary. Adult
mice lacking the ActRII gene, part of the signalling pathway for
activin, have defective reproductive performance and small
gonads. Interpretation is complicated by abnormal FSH
secretion, in addition to possibly deficient germ cell prolifera-
tion (Matzuk et al., 1995).
The results of this study localise both SMADs2 and 3 protein
in the human fetal ovary to the nuclei of somatic cells in the
ovarian stroma in between the clusters of germ cells. The pattern
of distribution for the activin receptors ALK4 and ACTRIIB we
have previously reported (Martins da Silva et al., 2004) is very
similar to that demonstrated for SMADs2 and 3 in the present
study. At 14 weeks gestation, prior to primordial follicle
formation, a minority of somatic cells in the ovarian stroma
express nuclear SMADs2 and 3. However, by 18 weeks
gestation, the majority of these somatic cells show nuclear
expression of both SMADs. SMADs2 and 3 were also
expressed by some somatic cells intermingled with germ
cells, although only by a minority of these cells. These
observations confirm the findings observed at the mRNA
level, where a near 2 fold increase in SMAD3 was observed
between 14 weeks gestation, i.e. prior to primordial follicleformation, and 17–18 weeks gestation, during primordial
follicle formation. A smaller rise in SMAD2 mRNA expression
did not reach statistical significance. These data are also in
keeping with the increase in activin βA expression identified
previously in the human fetal ovary (Martins da Silva et al.,
2004). Strikingly, SMADs 2 and 3 were also localised to the
nuclei of pre-granulosa cells surrounding oocytes that had
formed or were forming primordial follicles. Germ cell clusters
are surrounded by a basal lamina, separating them from the
somatic stromal cells out-with the clusters (Sawyer et al., 2002).
This suggests that a stromal somatic cell contribution to
granulosa cells is prevented before and during primordial
follicle formation, other than in the peripheral sub-epithelial
zone. With dual staining, activin βA-expressing oocytes within
the germ cell nests were demonstrated to be adjacent to somatic
cells expressing SMAD3, suggesting that these oocyte/somatic
cell groups may be proceeding to primordial follicle formation.
However the pre-granulosa cells surrounding newly-formed
primordial follicles expressed SMAD3 without expression of
activin βA by the oocyte. It is unclear whether this may reflect
persistent SMAD signalling, or whether another TGFβ family
member is active at that time.
Activin βB expression has also been demonstrated pre-
viously in the human fetal ovary. Immunostaining was more
widespread than with activin βA, with both germ cells and
somatic cells expressing the βB subunit, with the exception of
some of those seen at the periphery of the ovary (Martins da
Silva et al., 2004). Activin B may therefore be the relevant
factor for some of the SMAD2 and 3 identified in the ovarian
stroma.
Smad2 and Smad3 expression has been demonstrated in the
oocytes and pre-granulosa cells of the mid-trimester baboon
fetal ovary, and in the oocytes and granulosa cells of primordial
follicles in later gestations (Billiar et al., 2004). This distribution
of Smads 2 and 3, predominantly in the somatic cells, is similar
to the distribution demonstrated in this current work however
we did not detect any expression of SMAD2 or 3 by oocytes in
either the single or dual immunostaining experiments.
In addition to demonstrating the distribution of SMADs2 and
3, treatment of fetal ovarian cells with activin led to an increase
in phosphorylated SMAD2/3. Follistatin binds activin with high
affinity and neutralises its biological effect (Nakamura et al.,
1990; Schneyer et al., 1994). Further culture experiments
demonstrated that follistatin (in the absence of exogenous
activin) reduced phosphorylated SMAD2/3 expression to less
than 20% of control. These data therefore confirm that activin
signalling involves SMAD2/3 phosphorylation in the human
fetal ovary.
In order to identify the downstream transcriptional targets of
activin signalling in the fetal ovary we combined in vitro culture
of disaggregated fetal ovaries with quantitative RT-PCR to
examine candidate genes, namely SMAD2, SMAD3, KITLG and
FGF2. Activin has previously been reported to specifically
upregulate SMAD2 but not SMAD3 in immortalised human
extravillous trophoblast cells (Chen et al., 2003) and in cultured
granulosa cells isolated from adult hens (Schmierer et al., 2003).
Consistent with these reports, we detected a significant increase
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non-significant increase in SMAD3 expression. While the non-
significance of the increase in SMAD3may reflect experimental
variation, this raises the possibility that treatment with activin
selectively upregulates one arm of its signal transduction
machinery, and thus biases its effects towards the transcriptional
regulation of the subset of genes regulated by SMAD2 but not
SMAD3. Treatment of human extravillous trophoblast cells
with activin was also found to stimulate the expression of the
type I activin receptor (ActRI) (Chen et al., 2003). In
conjunction with the upregulation of SMAD2, this suggests
that activin is capable of promoting a positive feed-forward
mechanism in which the cellular response to activin is amplified
by increasing expression of its receptors and intracellular signal
transduction machinery.
Kitl and Fgf2 are important regulators of ovarian follicle
development, and have been shown to act synergistically to
promote primordial follicle development (Nilsson et al., 2001;
Nilsson and Skinner, 2004). Fgf2 has been reported to
upregulate the expression of kit ligand, although the reverse
does not occur (Nilsson and Skinner, 2004). Treatment with
activin did not change the level of expression of FGF2 mRNA,
suggesting that FGF2 is not a target of activin-mediated
transcriptional regulation, at least at this stage of development.
In contrast, KITLG expression in cultured ovarian cells was
reduced by greater than one third in response to treatment with
activin. This result is consistent with that recently reported by
Pangas et al. who found a significant upregulation of Kitl in the
ovaries of adult mice in which all activin beta-subunit genes
were conditionally deleted in granulosa cells only (Pangas et al.,
2007). Treatment of adult mouse granulosa cells with activin
repressed Kitl expression approximately seven-fold (Pangas et
al., 2007). This reduction is somewhat larger than that detected
in our cultures, and may reflect that not all bound activin is
removed during the disaggregation process, and that germ cells
present in our cultures continue to produce activin throughout
the course of the experiment. This is supported by the
demonstration that treatment with follistatin reduced SMAD2/
3 phosphorylation to 20% of controls, indicating that residual
activin is still present or being produced in our cultures and
having an effect that can be reduced by follistatin. Indeed,
Pangas et al. pre-treated their cultures with follistatin for 24 h
and conducted their experiments in the absence of contaminat-
ing germ cells (Pangas et al., 2007).
In addition to the demonstration here that somatic cell
expression of KITLG is repressed by activin, germ cell
expression of its cognate receptor c-Kit is also low in the
germ cell clusters where activin is expressed. c-Kit is expressed
by all germ cells at earlier developmental stages but is reduced
at entry to meiosis (Robinson et al., 2001; Hoyer et al., 2005;
Hutt et al., 2006; Fig. 4). Expression of c-Kit is again increased
as germ cells form primordial follicles. As kit ligand has been
shown to upregulate expression of c-Kit (Thomas et al., 2007),
it is likely that the repressive effect of activin on kit ligand
signalling will promote downregulation of the c-Kit receptor in
activin-producing germ cells. This is directly supported by our
findings which show that germ cells that express activin βA donot express c-Kit whereas c-Kit is expressed by other germ cells
within the same cluster. Stimulation of the c-Kit receptor in fully
grown oocytes has been shown to inhibit progress through
meiosis (Ismail et al., 1996, 1997), thus the role of activin in this
system may be indirectly to repress c-Kit expression thus
allowing germ cells to progress into meiosis until such a time as
primordial follicle formation is initiated, and meiotic arrest
resumed with the adjacent somatic cells having a key role in this
regulatory loop. The involvement of activin in the expression of
c-Kit and other known regulators of meiotic progression such as
Sycp1 that contribute to the regulation of primordial follicle
formation (Paredes et al., 2005) warrants further investigation.
In conclusion these results provide further evidence that
activin signalling via SMAD2/3 is important in the developing
human ovary before and at the time of primordial follicle
formation. The mechanism whereby activin enhances germ cell
development in the developing human ovary is indirect, with
the effects of germ cell-derived activin A mediated by adjacent
somatic cells. Somatic cell factors that may mediate the
reciprocal somatic cell to germ cell effect include kit ligand,
the receptor for which is expressed by germ cells. SMAD2/3
signalling also appears to be important in the granulosa cells of
newly-formed primordial follicles.Acknowledgments
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